Effect of Leflunomide Use on <SUP>68</SUP>Ga-DOTATATE Biodistribution in a Case With Neuroendocrine Tumor
CLINICAL NUCLEAR MEDICINE, vol.48, no.2, 2023 (SCI-Expanded, Scopus)
- Publication Type: Article / Editorial Material
- Volume: 48 Issue: 2
- Publication Date: 2023
- Doi Number: 10.1097/rlu.0000000000004517
- Journal Name: CLINICAL NUCLEAR MEDICINE
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE
- Kocaeli University Affiliated: No
Abstract
A 58-year-old man who underwent surgery for a well-differentiated neuroendocrine tumor of pancreatic origin was evaluated with Ga-68-DOTATATE PET/CT imaging in the follow-up period. After PET/CT findings consistent with disease remission, the patient was started on leflunomide treatment with the diagnosis of rheumatoid arthritis. The patient received leflunomide for 6 months. Then, Ga-68-DOTATATE PET/CT scan was repeated to evaluate the primary disease outcome. Besides the disease remission, we also observed alterations in DOTATATE uptakes of some tissues and organs. In this case, we present the changes in Ga-68-DOTATATE PET/CT scan findings after leflunomide use.